Hutchmed
Hutchmed, officially known as Hutchison China MediTech Limited, is a prominent biopharmaceutical company headquartered in Hong Kong. Founded in 2016, Hutchmed has rapidly established itself as a leader in the oncology and immunology sectors, focusing on the discovery, development, and commercialisation of innovative therapies. With a strong operational presence in China and the United States, Hutchmed has achieved significant milestones, including the successful launch of its flagship products, which are designed to address unmet medical needs in cancer treatment. The company’s unique approach combines cutting-edge research with a deep understanding of local markets, positioning it favourably within the competitive biopharmaceutical landscape. Hutchmed's commitment to advancing healthcare solutions has garnered recognition, making it a notable player in the global biopharmaceutical industry.
DitchCarbon Score
How does Hutchmed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Hutchmed's score of 38 is higher than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Hutchmed's reported carbon emissions
In 2024, Hutchmed reported total carbon emissions of approximately 120,000,000 kg CO2e, comprising 3,083,000 kg CO2e from Scope 1, 13,234,000 kg CO2e from Scope 2, and 104,710,000 kg CO2e from Scope 3 emissions. This represents a significant increase in emissions compared to 2023, where total emissions were about 78,000,000 kg CO2e, with Scope 1 at 320,000 kg CO2e, Scope 2 at 6,640,000 kg CO2e, and Scope 3 at 71,725,000 kg CO2e. Hutchmed has set ambitious reduction targets, aiming to decrease carbon emissions intensity by 30% for Scope 1 and by 10% for Scope 2 from a 2020 baseline by 2025. Additionally, the company plans to reduce emissions intensity from business air travel (Scope 3 downstream) by 10% from a 2019 baseline by 2025. Looking further ahead, Hutchmed has committed to achieving net-zero emissions across all scopes by 2050, focusing on sustainable pharmaceutical production and impactful partnerships. The emissions data is sourced directly from Hutchmed (China) Limited, with no cascading from a parent organization. The company is actively working towards its climate commitments while navigating the complexities of emissions management in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Scope 1 | 14,000 | 000,000 | 000,000 | 000,000 | 0,000,000 |
| Scope 2 | 5,073,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 |
| Scope 3 | 262,000 | 000,000 | - | 00,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Hutchmed is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
